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Abstract
 
Extracellular adenosine has been widely implicated in adaptive responses to hypoxia. The gen-
eration of extracellular adenosine involves phosphohydrolysis of adenine nucleotide intermediates,
and is regulated by the terminal enzymatic step catalyzed by ecto-5
 
 
 
-nucleotidase (CD73).
Guided by previous work indicating that hypoxia-induced vascular leakage is, at least in part,
controlled by adenosine, we generated mice with a targeted disruption of the third coding
exon of 
 
Cd73
 
 to test the hypothesis that CD73-generated extracellular adenosine functions in
an innate protective pathway for hypoxia-induced vascular leakage. 
 
Cd73
 
   
 
 mice bred and
gained weight normally, and appeared to have an intact immune system. However, vascular
leakage was significantly increased in multiple organs, and after subjection to normobaric hypoxia
(8% O
 
2
 
), 
 
Cd73
 
   
 
 mice manifested fulminant vascular leakage, particularly prevalent in the
lung. Histological examination of lungs from hypoxic 
 
Cd73
 
   
 
 mice revealed perivascular in-
terstitial edema associated with inflammatory infiltrates surrounding larger pulmonary vessels.
Vascular leakage secondary to hypoxia was reversed in part by adenosine receptor agonists or
reconstitution with soluble 5
 
 
 
-nucleotidase. Together, our studies identify CD73 as a critical
mediator of vascular leakage in vivo.
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Introduction
 
Acute increases in vascular leakage to macromolecules
closely coincide with tissue injury of many etiologies, and
can result in fluid loss, edema, and organ dysfunction (1–3).
Macromolecule transit across blood vessels is tightly con-
trolled, whereby relatively low macromolecular permeabil-
ity is essential for maintenance of a physiologically optimal
equilibrium between intravascular and extravascular com-
partments (4, 5). The normal vasculature is generally quite
impermeable to large macromolecules, and the predomi-
nant barrier (
 
 
 
90%) to movement of macromolecules
across a blood vessel wall is presented by the endothelium
(2, 6). Passage of macromolecules across a cellular mono-
layer can occur via either a paracellular route (i.e., between
cells) or a transcellular route (i.e., through cells). In condi-
tions of vascular leakage, macromolecules such as albumin
(molecular mass 
 
 
 
70 kD) appear to cross the cell mono-
layer by passing between adjacent endothelial cells (i.e.,
paracellular), although some degree of transcellular passage
may also occur (7, 8). Endothelial macromolecular perme-
ability is inversely related to macromolecule size, and such
permeability is also dependent on the tissue of origin. For
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example, endothelial cells in the cerebral circulation (i.e.,
blood–brain barrier) demonstrate an exceptionally low per-
meability (9, 10). Endothelial permeability may increase
markedly upon exposure to a variety of inflammatory com-
pounds (e.g., histamine, thrombin, reactive oxygen species,
leukotrienes, bacterial endotoxins) or adverse conditions
(e.g., hypoxia, ischemia; references 2, 11).
Previous studies indicated that extracellular nucleotide
metabolites, predominantly adenosine, may trigger an en-
dogenous protective mechanism during hypoxia and ische-
mia (12–15). Ecto-5
 
 
 
-nucleotidase (5
 
 
 
-NT, CD73) is a
membrane-bound glycoprotein that functions to hydrolyze
extracellular nucleoside monophosphates into bioactive nu-
cleoside intermediates (14). Surface-localized CD73 converts
AMP into adenosine, which in turn can activate transmem-
brane adenosine receptors or can be internalized through
dipyridamole-sensitive carriers (14). Adenosine generated
by CD73 expressed on barrier cell types (e.g., endothelia,
epithelia) has been shown to result in such diverse end-
points as regulation of endothelial permeability (16), atten-
uation of neutrophil adhesion (17), and stimulation of
epithelial electrogenic chloride secretion (responsible for
mucosal hydration; reference 18).
Endothelial cells of many origins express CD73 constitu-
tively. The primary function attributed to endothelial CD73
has been catabolism of extracellular nucleotides, although
CD73 may also mediate lymphocyte binding under some
circumstances (19). Rather little is known about the regula-
tion of endothelial CD73 expression, and whether this mol-
ecule contributes to the regulation of endothelial permeabil-
ity. Given that adenosine receptor activation (via adenosine
liberated from CD73) elevates intracellular cAMP, and that
elevated cAMP in endothelia promotes barrier function (2,
20), we considered the possibility that endothelial CD73
functions to regulate permeability. In support of this hy-
pothesis, it has been shown that CD73 expression is regu-
lated by hypoxia (21–24), primarily by hypoxia-inducible
factor-1 (21). However, there is no direct in vivo evidence
implicating CD73 in vascular barrier function.
In the present studies, we sought to determine whether
CD73 functionally regulates murine vascular leakage under
basal conditions or during hypoxia. Initial studies using the
selective CD73 inhibitor 
 
 
 
,
 
 
 
-methylene ADP (APCP; ref-
erence 25) revealed that inhibition of CD73 significantly in-
creases both basal and hypoxia-induced vascular leakage. To
more selectively address this issue, we generated 
 
Cd73
 
   
 
mice and used these mice to examine vascular leakage. Such
studies identified defects in vascular barrier regulation, par-
ticularly in the lung. Treatment of 
 
Cd73
 
   
 
 mice with the
adenosine receptor agonist 5
 
 
 
-(N-ethylcarboxamido)-aden-
osine (NECA) or reconstitution with purified 5
 
 
 
-NT re-
sulted in partial reversal of these defects. These studies iden-
tify CD73 as a critical regulator of vascular leakage in vivo.
 
Materials and Methods
 
Generation of Cd73-deficient Mice.
 
P1 bacteriophage clones con-
taining SV129 
 
Cd73
 
 genomic DNA were purchased from Ge-
nome Systems. An 8.9-kb BamHI restriction fragment containing
exon 3 was subcloned into Pzero (Invitrogen) to generate Pzero-
BamHI 81 (see Fig. 1 A). A targeting vector was constructed by
ligating a 1-kb fragment (short arm) amplified by PCR from in-
tronic sequence upstream of exon 3 and a 4.2-kb EcoRI frag-
ment (long arm) downstream of exon 3 into pBSneo, a modified
version of pBluescript II KS (
 
   
 
) with a neomycin resistance
cassette directionally ligated into BamHI and EcoRI sites (a gift
from T. Mak, Ontario Cancer Institute, Toronto, Canada). The
1-kb fragment contained engineered SacI sites to permit ligation
into the SacI site of the multicloning site of pBSneo. Both 
 
Cd73
 
genomic fragments were in the antisense orientation with respect
to 
 
neo
 
. Targeting vector DNA was CsCl purified before elec-
troporation into embryonic stem (ES) cells.
XhoI-linearized targeting vector was electroporated into CJ7
ES cells (a gift from T. Sato, University of Texas Southwestern
Medical Center, Dallas, TX) at a ratio of 30 
 
 
 
g vector DNA/5 
 
 
 
10
 
6
 
 ES cells. G418 was added to the media at 300 
 
 
 
g/ml after 24 h
of culture. Clones were picked after 7–9 d, expanded, and frozen
according to standard protocols. Clones were screened by PCR
to detect the presence of the targeted allele (see Fig. 1 C). The
forward PCR primer, 5
 
 
 
-AAGGAGGGGTGCATCTTGCTA-
TTC-3
 
 
 
, was from intronic sequence 5
 
 
 
 to that comprising
the short arm of the targeting vector and the reverse primer,
5
 
 
 
-CCAGCTCATTCCTCCCACTCATG-3
 
 
 
, was from within
the 
 
neo
 
 cassette. Two independent clones containing a gene-tar-
geted allele were generated. Gene targeting was confirmed by
Southern blotting with BamHI-digested genomic DNA and a
probe from intronic sequence 3
 
 
 
 to the long arm (see Fig. 1 D).
The gene-targeted allele generated a 7.4-kb band that was easily
distinguished from the 8.9-kb wild-type band. Blastocyst injec-
tions were performed at the University of Cincinnati Gene-Tar-
geted Mouse Service with both ES cell clones. Chimeras were
obtained from both of them, but germline transmission was ob-
tained with only one, 4G11. A single female 
 
Cd73
 
   
 
 mouse was
obtained and bred to C57BL/6 males. Her offspring were geno-
typed by PCR on tail DNA to detect the neo cassette. 
 
Cd73
 
   
 
mice were bred to each other to obtain 
 
Cd73
 
   
 
 mice and con-
trol 
 
Cd73
 
   
 
 and 
 
Cd73
 
   
 
 littermates. 
 
Cd73
 
   
 
 mice were back-
crossed to C57BL/6 mice for six generations for use in hypoxia
experiments.
 
Immunofluorescent Staining.
 
CD73 expression on hematopoi-
etic cells was evaluated by immunofluorescent staining with puri-
fied monoclonal antibody TY/23 (26) followed by PE-goat anti–rat
IgG (BD Biosciences). Rat IgG2a was used as a negative control.
Immunofluorescence was evaluated with a FACSCalibur and
CELLQuest software (Becton Dickinson).
 
Ecto-5
 
 
 
-NT Enzyme Assays.
 
Ecto-5
 
 
 
-NT enzyme activity was
evaluated by measuring the conversion of [
 
14
 
C]IMP to [
 
14
 
C]inosine
as described previously (27). APCP (Sigma-Aldrich) was used as a
specific inhibitor of CD73 (25). Thus, ecto-5
 
 
 
-NT enzyme activ-
ity was calculated as the portion of the total IMP-hydrolyzing ac-
tivity that could be inhibited by APCP. The results were ex-
pressed in nmoles IMP hydrolyzed/h/mg protein.
In subsets of experiments, CD73 activity was measured by
quantifying the conversion of etheno-AMP (E-AMP) to etheno-
adenosine (E-Ado) by reverse phase HPLC as described previously
(16). E-AMP and E-Ado were eluted with a 0–50% methanol/
H
 
2
 
O gradient mobile phase (2 ml/min over 10 min). Absorbance
was monitored at 260 nm, and ultraviolet absorption spectra were
obtained at chromatographic peaks. CD73 activity was expressed
as percent E-AMP conversion in this time frame. This methodol-
ogy of assaying phosphohydrolysis was validated between samples 
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using conversion of [
 
14
 
C-IMP] to [
 
14
 
C-inosine] (see previous para-
graph; unpublished data).
 
In Vivo Hypoxia Model.
 
Total organ vascular leakage was as-
sessed by intravascular administration of Evan’s blue (Sigma-
Aldrich) as described previously (23). In brief, Evan’s blue (0.2 ml
of 0.5% in PBS) was injected intravenously into 
 
Cd73
 
   
 
 or lit-
termate control 
 
Cd73
 
   
 
 animals that were exposed to nor-
mobaric hypoxia (8% O
 
2
 
, 92% N
 
2
 
) or room temperature air for
4 h (
 
n
 
 
 
 
 
 4–6 animals per condition). After experimental exposure,
the animals were killed, and the colon, skeletal muscle (gluteus
maximus), kidney, brain, heart, liver, and lungs were harvested.
Evan’s blue concentrations in organs were quantified after forma-
mide extraction (55
 
 
 
C for 2 h) by measuring absorbances at 610
nm with subtraction of reference absorbances at 450 nm. This
protocol was in accordance with National Institutes of Health
(NIH) guidelines for use of live animals and was approved by the
Institutional Animal Care and Use Committee at Brigham and
Women’s Hospital.
In subsets of experiments, mice were reconstituted with 5
 
 
 
-
NT purified from 
 
Crotalus atrox
 
 venom (Sigma-Aldrich). Pilot
dosing experiments revealed that 5
 
 
 
-NT could be used at con-
centrations as high as 500 U/kg i.p. without deleterious effects.
After administration of 5
 
 
 
-NT, animals were subjected to nor-
moxia or hypoxia, and examined for vascular leakage using
Evan’s blue as described before.
In other experiments, mice were administered the adenosine
A
 
2A
 
 receptor antagonist 4-(2-[7-amino-2-(2-furyl)[1,2,4]tria-
zolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM 241385;
Tocris Cookson Inc.; dosage of 1 mg/kg i.p. plus 1 mg/kg s.c.),
adenosine A
 
2B
 
 receptor antagonist 
 
N
 
-(4-cyanophenyl)-2-[4-
(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-
phenoxy]acetamide (MRS1754; a gift from K. Jacobson, Molec-
ular Recognition Section, NIH, Bethesda, MD; dosage of 1 mg/
kg i.p. plus 1 mg/kg s.c.) or the nonmetabolizable adenosine ana-
logue NECA (Sigma-Aldrich; dosage of 0.1 mg/kg i.p. plus 0.1
mg/kg s.c. based on previous work [28]). After administration of
drug, animals were subjected to normoxia or hypoxia, as indi-
cated, and examined for vascular leakage using Evan’s blue as de-
scribed before. For assessment of pulmonary edema, lungs were
collected, weighed, and dried by speed-vac. Weight differences
before and after drying were used to calculate lung water content.
 
Data Analysis.
 
Permeability data were compared by two-fac-
tor analysis of variance (ANOVA), or by Student’s 
 
t
 
 test where
appropriate. Values are expressed as the mean 
 
 
 
 SD from at least
three separate experiments.
 
Results
 
Generation of Cd73-deficient Mice. 
 
Previous studies im-
plicated extracellular adenosine in a protective pathway
regulating vascular leakage in multiple organs during hy-
poxia/ischemia, both in vitro and in vivo (16, 23). To di-
rectly address the role of CD73 in generating extracellular
adenosine, we generated a 
 
Cd73
 
-deficient mouse line. Our
strategy was to replace exon 3 with a neomycin resistance
cassette (Fig. 1), as our earlier work showed that exon 3
contained two crucial histidine residues required for ecto-
5
 
 
 
-NT enzyme activity (29). Using conventional gene tar-
geting methodology, a single 
 
Cd73
 
   
 
 female was obtained.
She was bred to C57BL/6 males to obtain additional
 
Cd73
 
   
 
 mice, and these were bred to each other to obtain
 
Cd73
 
   
 
, 
 
   
 
, and 
 
   
 
 mice. Offspring were obtained in
the expected 1:2:1 ratio.
 
CD73 Expression in Cd73 Gene-targeted Mice. 
 
CD73
expression was assessed in gene-targeted mice by the three
following methods: Northern blotting, immunofluorescent
staining of lymphoid cells, and ecto-5
 
 
 
-NT enzyme assays
on kidney extracts. Fig. 1 E shows a Northern blot of kid-
ney RNA from 
 
Cd73
 
   
 
 and 
 
Cd73
 
   
 
 mice. Three probes
were used. The exon 3 probe showed an absence of RNA
containing this exon from 
 
Cd73
 
   
 
 mice, as expected.
However, probes from both the 5
 
 
 
 and 3
 
 
 
 sides of exon 3
revealed low level expression (
 
 
 
10% of wild type) of an al-
Figure 1. Restriction maps of CD73 genomic DNA, targeting vector,
and recombined allele. (A) CD73 genomic DNA, including exon 3 and
intronic sequences used to construct the short (1 kb) and long arms (4.2 kb)
of the targeting vector. (B) CD73 targeting vector showing the antisense
orientation of the CD73 sequences relative to the neo cassette. (C) Re-
combined, gene-targeted CD73 allele. The flanking probe used for
Southern blots is shown, as are the positions of the PCR primers (arrows)
used for screening the ES cell clones. (D) Southern blot of genomic DNA
from Cd73   , Cd73   , and Cd73    mice. Genomic DNA was puri-
fied from mouse tails, digested with BamHI, and subjected to Southern
blotting by conventional methods. The probe was from intronic sequence
3  to the long arm as shown in C. The wild-type BamHI fragment is 8.9
kb, whereas that from the gene-targeted mice is 7.4 kb. (E) Northern blot
of kidney RNA from Cd73    and Cd73    mice. Triplicate Northern
blots were performed with 15  g of kidney RNA in each lane. Blots
were hybridized to the following probes: exon 2 (5  probe), exon 3, or
exon 4 (3  probe). Ethidium bromide staining was used to confirm equal
RNA loading.Vascular Leakage and CD73 1398
tered transcript, from which the neo cassette may have been
removed by splicing. Even though such splicing should not
produce a frame shift, we believe it is unlikely that this
transcript could lead to synthesis of a stable protein, as exon
3 contains two out of the four histidine residues that inter-
act with the two Zn 2 ions in each CD73 molecule (29)
and, thus, is likely crucial for maintaining the three-dimen-
sional structure of the protein. A preliminary Western
blotting experiment with our goat anti-CD73 antibody
(30) failed to reveal a smaller form of CD73 in kidney ex-
tracts from CD73 gene-targeted mice as would be ex-
pected if the 65 amino acids in exon 3 had been deleted
(unpublished data).
Cells from blood, thymus, spleen, lymph nodes, and
bone marrow from Cd73    and Cd73    mice were
stained for CD73 expression with monoclonal antibody
TY/23 (Fig. 2). The results demonstrated that Cd73   
mice lacked detectable cell surface expression of CD73
protein on any of their hematopoietic cells. The results of
the immunofluorescent staining were confirmed with ecto-
5 -NT enzyme assays on extracts of colon, lung, heart,
skeletal muscle, brain, liver, and kidney (Table I). As ex-
pected, enzyme activity was nearly undetectable in tissue
extracts from Cd73    mice. Interestingly, these assays also
revealed a 46-fold variation in CD73 5 -NT enzyme activ-
ity in different tissues from wild-type animals (e.g., com-
pare colon vs. skeletal muscle in Table I). Table I also
shows the levels of nucleotide hydrolyzing enzyme activi-
ties in each tissue that cannot be attributed to CD73 (i.e.,
nucleotidase and/or phosphatase activity that is not inhib-
itable by APCP). Such residual enzyme activity was not
distiguishable between wild-type and CD73-deficient mice
(not depicted) and varied by  20-fold in different tissues
(Table I), with colon having the highest level and skeletal
muscle the lowest (undetectable) level.
Evaluation of the Immune System in Cd73    Mice.  CD73
expression increases during lymphocyte development in
both mice (26) and humans (31). Furthermore, CD73 ex-
pression is markedly reduced on the lymphocytes of pa-
tients with a variety of immunodeficiency diseases (31).
These observations suggested that CD73 might be impor-
tant either for lymphocyte maturation or for the function
of mature lymphocytes. Therefore, Cd73    and Cd73   
mice were examined for the cellularity and composition of
the lymphoid organs at various ages up to 1 yr. No abnor-
malities were found (unpublished data). Lymphocyte func-
tion was also evaluated. Lymphocytes from Cd73    mice
showed normal proliferative responses to anti-CD3 and
LPS and made normal antibody responses to immunization
with ovalbumin (unpublished data). No tumors were ob-
served. In short, Cd73    mice appear to have a normal
immune system and are healthy when housed in a specific
pathogen-free animal facility.
Vascular Leakage in Cd73    Mice.  Based on previous
findings indicating that extracellular adenosine is critical for
control of vascular leakage in vitro and in vivo (16, 23), we
hypothesized that CD73 deficiency would significantly in-
fluence vascular leakage in vivo. To this end, we used nor-
mobaric hypoxia as a stimulus for vascular leakage in multi-
ple organs (23). During the initial period of hypoxia ( 30
min), Cd73    mice were more lethargic and less compli-
ant than their wild-type littermates. Nonetheless, all wild-
type and Cd73    mice recovered and survived the 4-h pe-
riod of hypoxia. Comparative analysis of basal permeability
(i.e., in normoxia) using Evan’s blue revealed that, in three
out of seven organs studied (lung, liver, and skeletal mus-
cle), vascular leakage was significantly increased in Cd73   
Figure 2. CD73 expression and function on leukocytes from Cd73   
and Cd73    mice. CD73 expression was evaluated on leukocytes from
lymph node, spleen, peripheral blood, bone marrow, and thymus from
Cd73    (left) and Cd73    (right) mice with monoclonal antibody TY/
23   PE–goat anti–rat IgG. Staining with an isotype-matched control an-
tibody is shown in the shaded histograms.
Table I.  Comparison of 5 -NT Levels in Various Tissues
Tissue
activity
APCP-inhibitable
5 -NT activity
Non-APCP
5 -NT
Cd73    Cd73    Pooleda
nmol/h/mg   SEM nmol/h/mg   SEM
Colon 1,523   116 9   3b 237   41
Lung 248   56 14   4b 73   4
Heart 171   64 1   0.1b 33   5
Muscle 33   56    0.9b undetectable
Brain 891   128 10   6b 89   16
Liver 347   26 1   0.1b 40   4
Kidney 799   158 6   4b 90   5
aNon-APCP inhibitable 5 -NT activity, pooled from both Cd73   
and Cd73    animals.
bIndicates significantly different than wild type (P   0.001) for n   7–9
mice per group.Thompson et al. 1399
mice (Fig. 3 A, P   0.025). Consistent with previous re-
ports (23, 32), normobaric hypoxia (8% O2, 92% N2) sig-
nificantly increased leakage of highly vascular organs of
wild-type mice, including the colon, lung, liver, muscle,
heart, and kidney (Fig. 3 B, P   0.025 by ANOVA). Fur-
thermore, under hypoxic conditions, vascular leakage was
increased (compared with Cd73   ) in all Cd73    organs
examined (P   0.01 by ANOVA), with the notable excep-
tion of the brain. Changes in overall vascular leakage
(Evan’s blue extravasation) between Cd73    and Cd73   
mice under both normoxic and hypoxic conditions were
also evident in open abdominal images taken at necropsy
(Fig. 3 C). These findings support the hypothesis that
CD73 is a critical determinant for permeability changes as-
sociated with adenine nucleotide metabolism, particularly
in the posthypoxic vasculature.
Influence of the CD73 Inhibitor APCP on Vascular Leakage.
To verify that CD73 catalyzes a crucial metabolic step for
maintenance of vascular barrier during hypoxia, we assessed
the consequences of the highly selective CD73 inhibitor
APCP (20 mg/kg i.p.) on Evan’s blue accumulation in
vivo in multiple organs from wild-type mice subjected to
Figure 3. Vascular leakage in Cd73-deficient mice in vivo. Cd73    mice (black bars) and age-, weight-, and gender-matched littermate controls
(white bars) were administered intravenous Evan’s blue (0.2 ml of 0.5% in PBS per mouse) and exposed to room temperature air (A) or normobaric hyp-
oxia (B, 8% O2, 92% N2) for 4 h. Animals were killed, and the colon (Co), lung (Lg), liver (Lv), muscle (Mu), heart (Ht), kidney (Kd), and brain (Br)
were harvested. Evan’s blue concentrations in organs were quantified as described in Materials and Methods. Data are expressed as mean   SD Evan’s
blue OD/50 mg wet tissue and are pooled from four to six animals per condition, where * indicates P   0.025 between Cd73    and Cd73    mice and
# indicates P   0.025 between hypoxia and normoxia. (C) Images of abdominal dissections from wild-type and Cd73    mice subjected to normoxia
and hypoxia for 4 h.
Figure 4. Influence of CD73 inhibition on vascular leakage in vivo. Age-, weight-, and gender-matched mice were administered APCP (20 mg/kg
i.p.) or an equal volume of PBS followed by intravenous Evan’s blue solution (0.2 ml of 0.5% in PBS per mouse) and exposed to room temperature air
(A) or to normobaric hypoxia (B, 8% O2, 92% N2) for 4 h. Animals were killed and the colon (Co), lung (Lg), liver (Lv), muscle (Mu), heart (Ht), kidney
(Kd), and brain (Br) were harvested. Evan’s blue concentrations in organs were quantified as described in Materials and Methods. Data are expressed as
mean   SD Evan’s blue OD/50 mg wet tissue and are pooled from four to six animals per condition where * indicates P   0.05 in comparisons between
APCP and PBS, and # indicates P   0.025 between hypoxia and normoxia. (C) HPLC analysis of CD73 5 -NT enzyme activity (conversion of 1 mM
E-AMP to E-Ado) in serum harvested at 4 h from normoxic animals administered  APCP (top) or  APCP (bottom).Vascular Leakage and CD73 1400
normoxia (room temperature air) or normobaric hypoxia
(8% O2, 92% N2) for 4 h. This protocol resulted in an 81.2  
8.5% decrease in circulating (serum) 5 -NT enzyme activ-
ity after 4 h (Fig. 4 C, P   0.01). As shown in Fig. 4 A,
permeability of the lung and colonic vasculature to Evan’s
blue was increased in normoxic mice preexposed to APCP
(P   0.05 compared with vehicle controls), suggesting that
CD73 contributes to basal barrier function in these organs.
APCP also increased vascular leakage in colon, lung, liver,
heart, and kidney of mice subjected to normobaric hypoxia
(Fig. 4 B, P   0.025 by ANOVA compared with vehicle
controls). Moreover, the APCP-mediated increases in per-
meability were amplified compared with those observed
under normoxic conditions (P   0.025 by ANOVA).
These results were further confirmed by a loss of APCP
response in Cd73    mice. Indeed, administration of
APCP to hypoxic Cd73    mice resulted in no significant
differences in Evan’s blue permeability compared with hy-
poxic Cd73    animals administered PBS; i.e., values for
Evan’s blue accumulation in the colon were 1.7   0.4 and
1.9   0.5 OD U/50 mg tissue for PBS and APCP, respec-
tively (p-value was NS). Paired experiments in wild-type
animals revealed a prominent influence by APCP; values
for Evan’s blue accumulation in the colon were 0.7   0.2
and 2.2   0.7 OD U/50 mg tissue for animals adminis-
tered PBS and APCP, respectively (P   0.01). Similar re-
sults were observed in the lung, liver, and kidney (unpub-
lished data). Together, these results verify our findings in
Cd73    mice and indicate that inhibition of CD73 results
in increased vascular leakage that is significantly amplified
in hypoxia.
Figure 5. Vascular leakage and reconstitution of Cd73    mice with
5 -NT. Cd73    mice (B and D) and age-, weight-, and gender-matched
littermate controls (A and C) were administered 5 -NT purified from C.
atrox venom (500 U/kg i.p.; black bars) or PBS (white bars) followed by
intravenous Evan’s blue solution (0.2 ml of 0.5% in PBS per mouse) and
exposed to room temperature air (A and B) or normobaric hypoxia (C
and D, 8% O2, 92% N2) for 4 h. Animals were killed and the colon (Co),
lung (Lg), liver (Lv), muscle (Mu), heart (Ht), kidney (Kd), and brain (Br)
were harvested. Evan’s blue concentrations in organs were quantified as
described in Materials and Methods. Data are expressed as mean   SD
Evan’s blue OD/50 mg wet tissue and are pooled from four to six animals
per condition where, in comparisons between 5 -NT and PBS, * indi-
cates P   0.05 and # indicates P   0.025.
Figure 6. Influence of adenosine receptor antagonists on hypoxia-
induced vascular leakage. Wild-type mice were administered either PBS
(Control), the A2B receptor antagonist MRS1754 (1 mg/kg i.p. plus 1
mg/kg s.c.) or the A2A receptor antagonist ZM241385 (1 mg/kg i.p. plus
1 mg/kg s.c.) followed by intravenous Evan’s blue solution (0.2 ml of
0.5% in PBS per mouse) and exposed to room air (black bars) or nor-
mobaric hypoxia (gray bars, 8% O2, 92% N2) for 4 h. Animals were killed,
and lungs were harvested. (A) Evan’s blue concentrations in organs were
quantified as described in Materials and Methods. Data are expressed as
mean   SD Evan’s blue OD/50 mg wet tissue and are pooled from four
animals per condition where * indicates P   0.01 between normoxia and
hypoxia and # indicates P   0.01 between treatment and control. (B)
Assessment of lung water content. Data are expressed as mean   SD mg
H2O/mg dry tissue, and are pooled from four animals per condition
where, in comparisons between hypoxia and normoxia, * indicates P  
0.01, # indicates P   0.05 between treatment and control, and ## indi-
cates P   0.025 between treatment and control.Thompson et al. 1401
Reconstitution of Cd73    Mice with 5 -NT.  As proof of
principle for the assertion that CD73 plays an important
role in regulation of vascular leakage during hypoxia,
Cd73    mice were reconstituted with 5 -NT purified
from C. atrox venom (500 U/kg i.p.) and subjected to nor-
moxia or normobaric hypoxia. This dose of 5 -NT resulted
in a 4.1   0.8-fold increase in plasma 5 -NT activity (P  
0.025; unpublished data). As shown in Fig. 5, this treat-
ment significantly enhanced vascular barrier function in all
animals tested (P   0.05 by ANOVA; Fig. 5, A–C for most
organs compared with vehicle control). Moreover, exoge-
nous 5 -NT dramatically rescued increased vascular leakage
observed in Cd73    animals exposed to hypoxia in all tis-
sues examined except brain (Fig. 5 D, P    0.025 by
ANOVA). Together, these studies provide strong evidence
that CD73 is a critical control point for vascular barrier
regulation, particularly during episodes of hypoxia.
Influence of Exogenous Adenosine Receptor Agonists on Vas-
cular Leakage.  Our results and those of others suggest that
CD73 promotes vascular barrier function by generating
adenosine to engage vascular adenosine receptors. Initially,
we determined the relative importance of individual aden-
osine A2 receptors on vascular leakage, using the lung as a
model organ. As shown in Fig. 6, administration of either
MRS 1754 (selective antagonist for the A2B receptor, dos-
age of 1 mg/kg i.p. plus 1 mg/kg s.c.) or ZM 241385 (se-
lective antagonist for the A2A receptor, dosage of 1 mg/kg
i.p. plus 1 mg/kg s.c.) significantly increased both pulmo-
nary vascular leakage (measured as Evan’s blue extravasa-
tion) and pulmonary edema (measured as lung water con-
tent) in normoxia, and particularly in hypoxia. Such results
indicate that both A2A and A2B receptors contribute to pul-
monary vascular leakage in hypoxia. Based on these find-
ings, we determined whether the general adenosine recep-
tor agonist NECA could rescue defects in vascular leakage
observed in Cd73    mice during hypoxia. As shown in
Fig. 7, administration of NECA (0.1 mg/kg i.p. plus 0.1
mg/kg s.c.) decreased vascular leakage in both hypoxia and
normoxia, particularly in the colon, lung, and liver. This
difference was notably more pronounced in Cd73    mice
subjected to hypoxia (P   0.025 by ANOVA), thus sup-
porting our hypothesis that CD73-generated extracellular
adenosine promotes barrier function during hypoxia, likely
through activation of A2A and A2B receptors. We acknowl-
edge that ZM241385 can also bind to the A2B receptor at
high concentrations; thus, it is possible that the A2B recep-
tor is the predominant receptor in adenosine-mediated
protection from vascular leakage in our studies.
Histology of Cd73    Lungs. Based on the findings of
increased pulmonary vascular leakage in APCP-treated ani-
mals, as well as significant defects in pulmonary vascular
barrier in Cd73    mice, we assessed the pulmonary vascu-
lar architecture in Cd73    mice. To do this, wild-type or
Cd73    mice were subjected to normoxia or hypoxia as
described before. Whole lungs were fixed with 10% forma-
lin at total lung capacity with a constant applied transpul-
Figure 7. Influence of the adenosine receptor agonist
NECA on vascular leakage of Cd73    mice. Cd73    mice
(B and D) and age-, weight-, and gender-matched littermate
controls (A and C) were administered the adenosine analogue
NECA (0.1 mg/kg i.p. plus 0.1 mg/kg s.c., black bars) or PBS
(white bars) followed by intravenous Evan’s blue solution (0.2
ml of 0.5% in PBS per mouse) and exposed to room tempera-
ture air (A and B) or normobaric hypoxia (C and D, 8% O2,
92% N2) for 4 h. Animals were killed, and the colon (Co),
lung (Lg), liver (Lv), muscle (Mu), heart (Ht), kidney (Kd),
and brain (Br) were harvested. Evan’s blue concentrations in
organs were quantified as described in Materials and Methods.
Data are expressed as mean   SD Evan’s blue OD/50 mg wet
tissue and are pooled from four to six animals per condition
where * indicates P   0.025 and # indicates P   0.01 be-
tween NECA and PBS.Vascular Leakage and CD73 1402
monary pressure of 25 cm H2O, sectioned, and stained. As
shown in Fig. 8 (A and B), histologic sections from wild-
type and Cd73    mice, respectively, kept under normoxic
conditions revealed normal pulmonary architecture with
the capillary endothelium lining the intertwining network
of anastomotic capillaries and a normal basement mem-
brane overlying the interstitium. Similar histologic exami-
nation of wild-type animals subjected to hypoxia revealed
subtle pulmonary edema predominantly in the perivascular
regions surrounding major conducting vessels, particularly
pulmonary arteries (Fig. 8 D). A small degree of inflamma-
tion, characterized by the presence of inflammatory cells,
was also evident in wild-type animals subjected to hypoxia.
However, lung sections from Cd73    animals subjected to
a 4-h period of hypoxia were very revealing (Fig. 8 C).
Consistent with our findings of a large degree of vascular
leakage, lungs from hypoxic Cd73    animals exhibited
perivascular edema surrounding the major pulmonary
blood vessels. Perivascular cuffing was also noted with oc-
casional large foci of inflammatory infiltrates (17). These le-
sions were associated with occasional disruption of epithe-
lial linings (Fig. 8 C, block arrow), although no significant
protein leakage into the alveolar space or distal lung was
evident. Given the perivascular localization of edema and
the absence of frank pulmonary edema, these histological
lesions appear to be associated with a hypoxia-induced al-
teration in large vessel barrier function, with preference for
pulmonary arteries.
To confirm the aforementioned observations, we objec-
tively compared lung water content (wet:dry ratio) in
Cd73    and Cd73    mice subjected to hypoxia in the
presence and absence of NECA. As shown in Fig. 8 E, hy-
poxia increased lung water content by 38   6% in Cd73   
mice (P   0.05). Similar analysis revealed a more pro-
nounced increase (69   7%, P   0.01) in Cd73    lungs,
thereby confirming our histologic findings of pulmonary
edema. In animals pretreated with NECA (Fig. 8 E), aden-
osine receptor activation partially rescued the hypoxia-
induced pulmonary edema in both Cd73    (16   3% de-
crease, P   0.05) and Cd73    lungs (32   6% decrease,
P   0.025). Interestingly, NECA alone significantly de-
creased lung water content in normoxic wild-type animals
(29   5% decrease, P   0.05), but not in Cd73    animals
(p-value was NS).
Discussion
Adenosine exerts autocrine and paracrine actions on
most cell types. Pathophysiologic conditions of hypoxia/
ischemia result in the elevation of extracellular adenosine,
with phosphohydrolysis of AMP by CD73 representing the
major pathway of extracellular adenosine formation. In the
present studies, we explored the in vivo relevance of CD73
in physiologic and pathophysiologic regulation of vascular
leakage. These studies revealed that, whereas Cd73    mice
are viable and appear to have a functionally intact immune
system, significant vascular leakage was observed in multi-
ple organs, particularly when mice were subjected to hy-
poxic stress.
Interstitial adenosine is critical for adaptation to hypoxia.
For example, extracellular adenosine production in the
myocardium by CD73 (14) has been demonstrated to con-
Figure 8. Characterization of lungs from Cd73    mice.
Wild-type (A and D) or Cd73    (B and C) mice were sub-
jected to normoxia (A and B) or hypoxia (C and D). Whole
lungs were fixed with 10% formalin at total lung capacity, sec-
tioned, and stained with hematoxylin and eosin. (A) A repre-
sentative image of a wild-type control animal (magnification,
100). (C) Perivascular interstitial edema (line arrows) and epi-
thelial disruption (block arrow) in Cd73    hypoxic mice
(magnification, 100). (D) Subtle perivascular interstitial edema
(line arrow) associated with wild-type hypoxic mice (magnifi-
cation, 100). (E) Assessment of lung water content in nor-
moxia (black bars) and hypoxia (gray bars) in the presence and
absence of NECA administration (0.1 mg/mg i.p. plus 0.1
mg/kg s.c.). Data are expressed as mean   SD mg H2O/mg
dry tissue and are pooled from three to four animals per condi-
tion where, in comparisons between hypoxia and normoxia, *
indicates P   0.025 and, in comparisons between NECA and
PBS, # indicates P   0.025.Thompson et al. 1403
tribute to cardiac preconditioning from brief periods of
ischemia (12, 14, 33, 34), and CD73 activity increases in
response to hypoxia/ischemia (21–24), attributable to a va-
riety of acute activation pathways. Recent studies provide
direct evidence that CD73 is transcriptionally induced by
hypoxia in pheochromocytoma cells in vitro (22) and in
epithelia and endothelia in vivo and in vitro (21, 23).
Mechanisms of CD73 induction involve both hypoxia-
inducible factor-1–mediated regulation of promoter activ-
ity (21) as well as feed-forward regulation of CD73 by
adenosine (35). Thus, previous work strongly implicated
CD73 as part of an innate protective response in hypoxic/
ischemic tissue through the generation of extracellular
adenosine, and provided the rationale for us to examine the
role of CD73 in vascular function in vivo.
Previous studies suggested that CD73 is a key compo-
nent of a protective pathway to maintain barrier function
in epithelia (21) and endothelia (23). For example, admin-
istration of the selective ecto-5 -NT inhibitor APCP to
mice by gavage significantly increased intestinal epithelial
permeability (21). Furthermore, the barrier-promoting
function of ATP released from activated neutrophils in
vitro was found to be dependent on ATP hydrolysis to
adenosine via the coordinated action of CD39 (ecto-apy-
rase) and CD73 (23). Here, we provide several new lines of
evidence from in vivo studies to support our hypothesis
that CD73 functions to protect barrier function in multiple
organs. Initial findings of increased vascular leakage (Evan’s
blue extravasation) that was enhanced by hypoxia in
Cd73    animals fortify the developing idea of CD73 as an
important adaptive enzyme during hypoxia. Additional
support for this hypothesis was provided by the observation
that inhibition of CD73 using APCP in wild-type animals
resulted in increased vascular leakage in highly vascularized
tissues. Finally, Cd73    animals were afforded a degree of
protection by reconstitution with purified C. atrox 5 -NT,
implying that CD73 may provide a potential target for
therapeutic development. Together, these new findings
implicate extracellular adenosine as a key control point for
regulation of vascular leakage in multiple tissues.
It is important to note that we observed quite significant
differences in vascular leakage between different tissues and
with various treatments (e.g., APCP and NECA). The fac-
tors responsible for these tissue- and treatment-specific dif-
ferences in vascular leakage are complex and incompletely
understood. Clearly, the level of CD73 5 -NT enzyme ac-
tivity in a given tissue is not the crucial factor. The colon
has the highest expression of the tissues examined, yet
shows only a modest increase in vascular leakage in hy-
poxic Cd73    mice. Alternately, 5 -NT activity is very
low in skeletal muscle ( 2% of that in colon), yet muscle
tissue shows an increase in vascular leakage comparable to
that observed in other tissues such as kidney with as much
as 24-fold higher 5 -NT enzyme activity. One factor may
be the level of AMP-hydrolyzing activity attributed to en-
zymes other than CD73 (i.e., other nucleotidases and/or
phosphatases). Of the tissues we studied, colon had the
highest level of nucleotide-hydrolyzing activity that could
not be inhibited by APCP, whereas skeletal muscle had the
lowest (undetectable) level (Table I). The differences in
vascular leakage observed under hypoxic conditions for
Cd73    mice versus wild-type mice treated with APCP
may reflect limited access of APCP to some tissues and/or
the difference between Cd73    mice that are Cd73-defi-
cient since birth as compared with Cd73    mice that be-
come Cd73 deficient acutely after treatment with APCP.
Another confounding difference could be variations in
adenosine receptor expression in the various tissues studied.
Although the present studies are the first to define a
physiological role for CD73 in barrier function in vivo,
these results also raise a number of important questions.
First, it will be important to determine the exact source of
extracellular nucleotides, particularly during hypoxia and
inflammation. Neutrophils are known to accumulate at
sites of hypoxia and inflammation and are demonstrated
sources of adenine nucleotides (in the form of 5 -AMP [18]
and ATP [23]). Moreover, nucleotides released can be me-
tabolized to active intermediates (e.g., adenosine) via bio-
chemical crosstalk pathways involving two different cell
types (16–18). Activated platelets comprise an additional
reservoir of extracellular adenine nucleotides, particularly
ATP. Given the recent evidence implicating ATP/ADP
phosphohydrolysis by CD39 during hypoxia and ischemia
(23, 36), it is possible that these types of circulating cells
provide a readily available substrate pool for vascular barrier
regulation by CD73. Second, we do not know which
adenosine receptors predominate in this vascular response.
Four subtypes of G protein–coupled adenosine receptors
exist, designated A1, A2A, A22B, and A3 (14). These recep-
tors are classified according to utilization of pertussis toxin–
sensitive pathways (A1 and A3) or adenylate cyclase activa-
tion pathways (A2A and A2B). Our evidence indicates that
adenosine promotes vascular barrier and because elevation
of cAMP is associated with increased barrier function (2), it
is likely that our results represent activation of A2A and/or
A2B receptors. The A2B receptor may well be the target, as
A2B receptor mRNA is up-regulated by hypoxia, and A2B
receptor antagonists neutralize ATP-mediated changes in
posthypoxic endothelial barrier function. Indeed, we pro-
vide evidence using MRS 1754 and ZM241385 that it is
likely that both the A2A and A2B receptors contribute to the
changes in vascular barrier during hypoxia. An A2B receptor
gene-targeted mouse will probably be required to confirm
this conclusion with certainty. Alternatively, inosine could
mediate these responses. We think this is unlikely because
inosine binds primarily to the A3 receptor (37) (a class of
adenosine receptor that mediates decreased cAMP), and it
is likely that Cd73    mice retain the ability to generate
inosine through the combined action of AMP deaminase
and cytoplasmic nucleotidases. Third, we do not know ex-
act molecular mechanisms of adenosine-mediated barrier
regulation. Although our previous in vitro work has sug-
gested that adenosine-mediated phosphorylation of tight
junction-associated proteins such as vasodilator-stimulated
phosphoprotein may be critical in both epithelial and en-
dothelial permeability (38, 39), it is not known if theseVascular Leakage and CD73 1404
pathways function at the whole tissue level in vivo. Finally,
we do not understand why vascular barrier function is bet-
ter maintained in the brains of Cd73    mice even under
conditions of hypoxia. However, it is perhaps not surpris-
ing that the response of brain might be anomalous, given
the unique properties of the blood–brain barrier. Perhaps
the mechanisms that regulate vascular leakage in the blood–
brain barrier are less dependent on adenosine. These issues
remain to be resolved.
A consistent finding throughout these experiments was a
predominant influence of CD73 in pulmonary vascular
leakage. Indeed, lung vascular leakage was highly influ-
enced by exogenous administration of APCP in wild-type
animals, and the vascular leakage phenotype was most
prominent in the lungs of Cd73    mice. Based on these
observations, we addressed lung histology in more detail.
Closer examination revealed perivascular interstitial edema
with inflammatory infiltrates surrounding the larger con-
ducting vessels of the pulmonary vasculature in Cd73   
animals. This phenotype was particularly prevalent in
Cd73    mice subjected to hypoxia and was confirmed by
assessment of lung wet/dry ratios indicating a  65% in-
crease in lung water content. The mechanism of such vas-
cular leakage remains undetermined.
In summary, these results identify CD73-catalyzed aden-
osine production as a critical control point for maintenance
and regulation of vascular barrier function in multiple tis-
sues during hypoxia. Studies in the lungs of hypoxic
Cd73    mice revealed segmental perivascular leakage in-
volving macrovascular barrier disruption. Our ability to re-
constitute barrier function with C. atrox 5 -NT suggests
that CD73 might function as a therapeutic target for disor-
ders involving vascular leakage syndromes.
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